Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
37 studies found for:    " January 02, 2013":" February 01, 2013"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" January 02, 2013":" February 01, 2013"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM)
Condition: HIV Infection
Interventions: Behavioral: 3MV;   Behavioral: PCC;   Drug: Emtricitabine/tenofovir (FTC/TDF (Truvada®))
2 Active, not recruiting
Has Results
Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: E/C/F/TAF;   Drug: E/C/F/TDF;   Drug: E/C/F/TDF Placebo;   Drug: E/C/F/TAF Placebo
3 Completed Renal, Endocrine, and Bone Changes in Response to FTC/TDF in Uninfected Young Men Who Have Sex With Men (YMSM).
Condition: HIV Infection
Intervention: Drug: FTC/TDF (Truvada®)
4 Completed Feasibility of Using a Structured Daily Diary
Condition: HIV Infection
Intervention: Behavioral: Structured daily diary
5 Active, not recruiting Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123 vaccine;   Biological: NYVAC-HIV-PT1 vaccine;   Biological: NYVAC-HIV-PT4 vaccine;   Biological: Placebo for DNA-HIV-PT123 vaccine;   Biological: Placebo for NYVAC-HIV-PT1 vaccine;   Biological: Placebo for NYVAC-HIV-PT4 vaccine
6 Completed Folinic Acid and Vascular Reactivity in HIV
Condition: Human Immunodeficiency Virus (HIV) Infection
Interventions: Dietary Supplement: Folinic Acid;   Other: Placebo
7 Enrolling by invitation IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children
Conditions: HIV Positive;   Malnourished
Intervention: Drug: ZDV+3TC+LPV/r
8 Completed Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy
Condition: Human Immunodeficiency Virus
Interventions: Drug: Raltegravir;   Drug: Fluconazole;   Drug: Azithromycin;   Drug: Albendazole;   Drug: Isoniazid;   Dietary Supplement: Ready to Use Supplementary Food
9 Recruiting CVCTPlus: A Couples-Based Approach to Linkage to Care and ARV Adherence
Condition: HIV
Intervention: Behavioral: CVCTPLUS
10 Completed Effects of Newly-Initiated QUAD Therapy on Aortic/Coronary Inflammation in ART-Naïve Infected Patients
Condition: HIV
Intervention:
11 Completed An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc
Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: Continued Access Arm
12 Recruiting Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at High Risk of Acquiring HIV-1 Infection
Condition: HIV Infections
Intervention: Drug: Raltegravir
13 Recruiting Pediatric HIV Disclosure Intervention
Condition: Paediatric HIV Diagnosis Disclosure
Intervention: Behavioral: Cognitive behavioral intervention to support pediatric HIV disclosure
14 Active, not recruiting Redirected MazF‐CD4 Autologous T Cells for HIV Gene Therapy
Condition: HIV
Intervention: Genetic: Autologous CD4+ T cells genetically modified with a retroviral vector expressing the MazF endoribonuclease gene (MazF‐T), given via intravenous infusion.
15 Completed The Effect of Antacids and Multivitamins on Raltegravir
Condition: HIV
Interventions: Dietary Supplement: Multivitamins;   Dietary Supplement: Sodium bicarbonate;   Drug: Maalox Plus extra;   Drug: Raltegravir 400 mg
16 Completed Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine
Condition: HIV
Intervention: Drug: ATRIPLA
17 Active, not recruiting The HIV Testing Using Enhanced Screening Techniques in Emergency Departments Trial
Condition: Rapid HIV Screening
Interventions: Other: A: Nontargeted rapid HIV screening;   Other: B: Enhanced targeted rapid HIV screening;   Other: C: Traditional targeted rapid HIV screening
18 Active, not recruiting Pulmonary Substudy: A Substudy of Strategic Timing of AntiRetroviral Treatment (START)
Conditions: Chronic Obstructive Pulmonary Disease;   HIV
Intervention:
19 Unknown  Mater-Bronx Rapid HIV Testing Project.
Condition: Human Immunodeficiency Virus
Interventions: Other: No participant choice of counselor;   Other: Participant choice of counselor
20 Completed A Demonstration Project to Add Pre- or Post-exposure Prophylaxis to Combination HIV Prevention Services
Condition: HIV Prevention
Intervention: Drug: emtricitabine 200mg/tenofovir 300mg

   Previous Page Studies Shown (1-20) Next Page (21-37) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.